PL4073044T3 - Nowe inhibitory BRAF jako związki przełamujące paradoks - Google Patents

Nowe inhibitory BRAF jako związki przełamujące paradoks

Info

Publication number
PL4073044T3
PL4073044T3 PL20817376.5T PL20817376T PL4073044T3 PL 4073044 T3 PL4073044 T3 PL 4073044T3 PL 20817376 T PL20817376 T PL 20817376T PL 4073044 T3 PL4073044 T3 PL 4073044T3
Authority
PL
Poland
Prior art keywords
braf inhibitors
new
paradox
breakers
paradox breakers
Prior art date
Application number
PL20817376.5T
Other languages
English (en)
Inventor
Cosimo Dolente
David Stephen HEWINGS
Daniel Hunziker
Daniela Krummenacher
Piergiorgio Francesco Tommaso PETTAZZONI
Juergen Wichmann
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL4073044T3 publication Critical patent/PL4073044T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Luminescent Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Glass Compositions (AREA)
PL20817376.5T 2019-12-10 2020-12-08 Nowe inhibitory BRAF jako związki przełamujące paradoks PL4073044T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19214867 2019-12-10
PCT/EP2020/084969 WO2021116050A1 (en) 2019-12-10 2020-12-08 New braf inhibitors as paradox breakers

Publications (1)

Publication Number Publication Date
PL4073044T3 true PL4073044T3 (pl) 2025-05-19

Family

ID=68848068

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20817376.5T PL4073044T3 (pl) 2019-12-10 2020-12-08 Nowe inhibitory BRAF jako związki przełamujące paradoks

Country Status (21)

Country Link
US (1) US20220298145A1 (pl)
EP (1) EP4073044B1 (pl)
JP (1) JP7788380B2 (pl)
KR (1) KR20220112777A (pl)
CN (1) CN114746405B (pl)
AR (1) AR120697A1 (pl)
AU (1) AU2020403082A1 (pl)
BR (1) BR112022010633A2 (pl)
CA (1) CA3158541A1 (pl)
CL (1) CL2022001492A1 (pl)
CO (1) CO2022007621A2 (pl)
CR (1) CR20220252A (pl)
ES (1) ES3018143T3 (pl)
IL (1) IL292349B2 (pl)
MX (1) MX2022006711A (pl)
PE (1) PE20221027A1 (pl)
PH (1) PH12022551118A1 (pl)
PL (1) PL4073044T3 (pl)
TW (1) TWI857190B (pl)
WO (1) WO2021116050A1 (pl)
ZA (1) ZA202204092B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI4073065T1 (sl) 2019-12-10 2025-06-30 F. Hoffmann-La Roche Ag Novi derivati metilkinazolinona
MX2022015703A (es) 2020-06-09 2023-01-24 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
AU2022290851A1 (en) 2021-06-08 2023-11-23 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant braf
TW202409040A (zh) 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
EP4584258A1 (en) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
CN118126051A (zh) * 2022-12-02 2024-06-04 C4医药公司 突变体braf降解剂的多晶型物及其制备方法
JP2025541200A (ja) 2022-12-15 2025-12-18 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト がん処置のための併用療法
EP4634171A1 (en) 2022-12-15 2025-10-22 F. Hoffmann-La Roche AG Process for the preparation of a quinazolinone derivative
CN122070273A (zh) 2023-10-23 2026-05-19 豪夫迈·罗氏有限公司 用于制备 (3r)-氟吡咯烷盐酸盐的新方法
WO2025108405A1 (zh) 2023-11-22 2025-05-30 西藏海思科制药有限公司 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途
WO2025153057A1 (zh) 2024-01-17 2025-07-24 海思科医药集团股份有限公司 一种含braf抑制剂的药物组合物及其在医药上的应用
WO2025261943A1 (en) 2024-06-18 2025-12-26 F. Hoffmann-La Roche Ag Anti-cancer combinations comprising mosperafenib and folfox or folfiri
WO2026037755A1 (en) 2024-08-13 2026-02-19 F. Hoffmann-La Roche Ag New methylquinazolinone derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111278A2 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
AU2009226136B2 (en) * 2008-03-17 2013-08-15 Ambit Biosciences Corporation Quinazoline derivatives as RAF kinase modulators and methods of use thereof
CN102858754A (zh) * 2009-08-28 2013-01-02 阵列生物制药公司 Raf抑制剂化合物及其使用方法
EP2501236B1 (en) * 2009-11-18 2017-03-29 Plexxikon Inc. N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer
PE20141360A1 (es) * 2011-02-07 2014-10-13 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
CA2882410A1 (en) * 2012-09-19 2014-03-27 Novartis Ag Dihydropyrrolidino-pyrimidines as kinase inhibitors
BR112017025045A2 (pt) * 2015-05-22 2018-08-07 Plexxikon Inc plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療braf相關的疾病和失調症之化合物
SI4073065T1 (sl) * 2019-12-10 2025-06-30 F. Hoffmann-La Roche Ag Novi derivati metilkinazolinona
MX2022015703A (es) * 2020-06-09 2023-01-24 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.

Also Published As

Publication number Publication date
AU2020403082A1 (en) 2022-05-12
TWI857190B (zh) 2024-10-01
TW202136218A (zh) 2021-10-01
PE20221027A1 (es) 2022-06-16
CR20220252A (es) 2022-07-11
BR112022010633A2 (pt) 2022-08-16
MX2022006711A (es) 2022-07-12
CL2022001492A1 (es) 2023-02-24
CO2022007621A2 (es) 2022-08-30
EP4073044B1 (en) 2025-02-19
ZA202204092B (en) 2022-12-21
PH12022551118A1 (en) 2023-09-18
EP4073044C0 (en) 2025-02-19
IL292349A (en) 2022-06-01
US20220298145A1 (en) 2022-09-22
JP7788380B2 (ja) 2025-12-18
ES3018143T3 (en) 2025-05-14
EP4073044A1 (en) 2022-10-19
JP2023505300A (ja) 2023-02-08
WO2021116050A1 (en) 2021-06-17
CN114746405B (zh) 2024-03-26
IL292349B1 (en) 2025-12-01
AR120697A1 (es) 2022-03-09
KR20220112777A (ko) 2022-08-11
CA3158541A1 (en) 2021-06-17
IL292349B2 (en) 2026-04-01
CN114746405A (zh) 2022-07-12

Similar Documents

Publication Publication Date Title
ZA202204092B (en) New braf inhibitors as paradox breakers
IL292432B1 (en) Pyridazinones as PARP7 inhibitors
IL285302A (en) Compounds, preparations and methods
GB201903287D0 (en) Composition
IL291172A (en) new compounds
SI4051688T1 (sl) Inhibitorji CD73
SG11202011544UA (en) Vmat2 inhibitor compounds, compositions, and methods relating thereto
EP3355989A4 (en) COMPOSITION WITH IMPROVED EFFICIENCY
GB201912061D0 (en) Composition
GB201917899D0 (en) New composition
IL287120A (en) Compounds, preparations and methods
GB201907225D0 (en) Composition
GB201911454D0 (en) Composition
GB201902054D0 (en) Composition
GB201916122D0 (en) New compositions
GB201916217D0 (en) Composition
GB201903406D0 (en) Composition
GB201903340D0 (en) Composition
GB201908044D0 (en) Dopamine-B-Hydroxylase inhibitors
GB201916117D0 (en) New compositions
GB201916130D0 (en) New compositions
GB201916119D0 (en) New compositions
GB201916121D0 (en) New compositions
GB201905476D0 (en) MAPA4K4 Inhibitors
GB201902276D0 (en) New composition